Evercore ISI initiated coverage of TransMedics (TMDX) with an Outperform rating and $155 price target There is a misunderstanding among investors that the cost of TransMedics’ services are materially higher than competitive alternatives, but the firm’s analysis shows total costs are similar, despite materially better patient outcomes, the analyst tells investors. The firm cites the company’s “differentiated” end-to-end organ transplant offering and “impressive financial outlook” for its Outperform rating on TransMedics.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- Balanced Outlook on TransMedics Group: Ambitious Growth Amidst Market Challenges
- Black Diamond, TransMedics, Duolingo, AT&T, Coherus: Trending by Analysts
- TransMedics initiated with a Hold at Stifel
- TransMedics Group: Undervalued Leader in Organ Transplantation with Strong Growth Potential
- Strategic Growth Potential and Competitive Edge: Buy Rating for TransMedics Group